Balversa Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Erdafitinib

Indications/Uses

Adult patients w/ locally advanced or metastatic urothelial carcinoma w/ susceptible fibroblast growth factor receptor 3 genetic alterations whose disease has progressed on or after at least 1 line of prior systemic therapy.

Dosage/Direction for Use

Adult ≥18 yr Initially 8 mg once daily. Individualized up-titration based on serum phosphate (PO₄) conc & drug-related toxicity, may up-titrate dose to 9 mg daily if serum PO₄ conc is <9.0 mg/dL & there is no drug-related toxicity.

Administration

May be taken with or without food: Swallow whole.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EN01 - erdafitinib ; Belongs to the class of Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Balversa FC tab 3 mg

Packing/Price

1's

Form

Balversa FC tab 4 mg

Packing/Price

1's

Form

Balversa FC tab 5 mg

Packing/Price

1's

Balversa

erdafitinib

Manufacturer:

Janssen-Cilag